论文部分内容阅读
States of growth hormone (GH) resistance, such those observed in Larons dwarf patients, are characterized by mutations in the GH receptor (GHR), decreased serum and tissue IGF-1 levels, impaired glucose tolerance, and impaired skeletal acquisition.IGF-1 replacement therapy in such patients increases growth velocity but does not normalize growth.Herein we combined the GHresistant (GHR knockout, GHRKO) mouse model with mice expressing the hepatic Igf-1 transgene (HIT) to generate the GHRKO-HIT mouse model.